Consensus and controversies in the science of endophthalmitis management: Basic research and clinical perspectives.


Journal

Progress in retinal and eye research
ISSN: 1873-1635
Titre abrégé: Prog Retin Eye Res
Pays: England
ID NLM: 9431859

Informations de publication

Date de publication:
11 2023
Historique:
received: 25 07 2023
revised: 17 09 2023
accepted: 25 09 2023
medline: 10 11 2023
pubmed: 15 10 2023
entrez: 14 10 2023
Statut: ppublish

Résumé

Infectious endophthalmitis is a severe intraocular infection caused by bacteria, or less commonly by fungi. It can occur after penetrating eye procedures, trauma, or the spread of infection from contiguous structures or via emboli from distant organs. Because of the time-critical nature of the treatment, endophthalmitis is treated with the clinical diagnosis and modified by the microbiological report of the intraocular contents. The current strategy for managing endophthalmitis relies on pre-clinical literature, case series, and one large multi-center randomized clinical trial on post-cataract surgery endophthalmitis. Culture-susceptibility of the microorganisms from undiluted vitreous guides the definitive treatment in non-responsive cases. Strategies to reduce the incidence of endophthalmitis after penetrating eye procedures have been developed concurrently with refined means of treatment. Despite these advances, outcomes remain poor for many patients. Although consensus articles have been published on managing endophthalmitis, treatment patterns vary, and controversies remain. These include (1) the use of newer methods for early and precise microbiological diagnosis; (2) the choice of intravitreal antibiotics; (3) the need for systemic therapy; (4) early and complete vitrectomy. Here, we review the current consensus and address controversies in diagnosing and managing endophthalmitis. This review is intended to familiarize physicians and ophthalmologists with different aspects of endophthalmitis management to make informed decisions.

Identifiants

pubmed: 37838286
pii: S1350-9462(23)00057-5
doi: 10.1016/j.preteyeres.2023.101218
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101218

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Auteurs

Taraprasad Das (T)

Anant Bajaj Retina Institute, Srimati Kanuri Santhamma Centre for Vitreoretinal Disease, L V, Prasad Eye Institute, Hyderabad, India. Electronic address: tpd@lvpei.org.

Joveeta Joseph (J)

Jhaveri Microbiology Center, L V Prasad Eye Institute, Hyderabad, India. Electronic address: joveeta@lvpei.org.

Matthew P Simunovic (MP)

Save Sight Institute, University of Sydney, NSW, 2006, Australia; Sydney Eye Hospital, 8 Macquarie St., Sydney, NSW, 2000, Australia. Electronic address: matthew.simunovic@sydney.edu.au.

Andrzej Grzybowski (A)

Institute for Research in Ophthalmology, Foundation for Ophthalmology Development, Poznan, Poland. Electronic address: ae.grzybowski@gmail.com.

Kuan-Jen Chen (KJ)

Department of Ophthalmology, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan. Electronic address: cgr999@gmail.com.

Vivek Pravin Dave (VP)

Anant Bajaj Retina Institute, Srimati Kanuri Santhamma Centre for Vitreoretinal Disease, L V Prasad Eye Institute, Hyderabad, India. Electronic address: vivekdave@lvpei.org.

Savitri Sharma (S)

Jhaveri Microbiology Center, L V Prasad Eye Institute, Hyderabad, India. Electronic address: savitri@lvpei.org.

Patrick Staropoli (P)

Anant Bajaj Retina Institute, Srimati Kanuri Santhamma Centre for Vitreoretinal Disease, L V Prasad Eye Institute, Hyderabad, India. Electronic address: 97patrickstar@gmail.com.

Harry Flynn (H)

Bascom Palmer Eye Institute, Miami, FL, USA. Electronic address: hflynn@med.miami.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH